Melinta Therapeutics focuses on discovering, developing, and commercializing antibiotics that address life-threatening bacterial infections, particularly those caused by drug-resistant ESKAPE pathogens. Its lead product, Baxdela (delafloxacin), has U.S. FDA approval for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and received priority review under the GAIN Act. The company plans to expand Baxdela into additional indications, including community-acquired bacterial pneumonia, and is leveraging Nobel Prize-winning science to create an entirely new class of antibiotics against multi- and extremely-drug-resistant organisms. Headquartered in New Haven, Connecticut, with offices in Lincolnshire, Illinois, Melinta is backed by investors such as Vatera Healthcare Partners and Malin Corporation plc. The firm positions itself as a key player in combating the global public-health crisis of antibiotic resistance. This financing provides the capital needed to commercialize Baxdela’s first indication and support further clinical studies while retiring earlier debt. The structure of the financing—with a mix of debt and equity and cash-sparing repayment terms—helps preserve the company’s ownership structure and financial flexibility.

Total raised

$257M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Jun 2017